VANCOUVER, British Columbia, April 27, 2011 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) today announced that preliminary results from the Leber Congenital Amaurosis (LCA) patient cohort in its on-going Phase 1b clinical proof-of-concept study of QLT091001 will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, FL.
